Monoclonal antibodies in renal transplantation: Old and new

Nephrology Dialysis Transplantation

Volumn 19, Issue 2, 2004, Pages 297-300

  Kuypers, Dirk R J ^a   Vanrenterghem, Yves F C ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Campath1 H; CTLA4Ig; Kidney transplantation; Monoclonal antibodies

Indexed keywords

ALEMTUZUMAB; ALLOANTIGEN; AZATHIOPRINE; B7 ANTIGEN; BASILIXIMAB; CALCINEURIN INHIBITOR; CD11 ANTIGEN; CD28 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; CD52 ANTIGEN; CD86 ANTIGEN; CYCLOSPORIN A; CYTOKINE; DACLIZUMAB; EFALIZUMAB; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LEA29Y; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ODULIMOMAB; OKT 3; RAPAMYCIN; STEROID; T LYMPHOCYTE RECEPTOR; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CAPILLARY LEAK SYNDROME; CHILL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; EDITORIAL; FEVER; HUMAN; HYPERTENSION; INFECTION COMPLICATION; INFECTION RISK; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; LUNG EDEMA; MENINGOENCEPHALITIS; MULTICENTER STUDY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TRANSPLANTATION IMMUNOLOGY;

EID: 1042303657     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg555     Document Type: Editorial

References (22)

1. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985; 313: 337-342
2. Vincenti F, Kirkman R, Light S et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161-165
3. Nashan B, Light S, Hardie IR, Lin A, Johnson JR for the Daclizumab Double Therapy Study Group. Transplantation 1999; 67: 110-115
4. Ciancio G, Burke GW, Suzart K et al. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation 2002; 73: 1100-1106
5. Vincenti F, Pace D, Birmbaum J, Lantz M. Pharmacokinetic and pharmacodynamic studies of one or two doses of Daclizumab in renal transplantation. Am J Transplant 2003; 3: 50-52
6. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP for the CHIB 201 International Study Group. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350: 1193-1198
7. Kahan BD, Rajagopalan PR, Hall M, for the United States Simulect Renal Study Group. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantation 1999; 67: 276-284
8. Vincenti F, Ramos E, Bratstrom C et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001; 71: 1282-1287
9. Flechner SM, Goldfarb D, Modlin C et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomised trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070-1076
10. Light JA, Sasaki TM, Ghasemian R, Barhyte DY, Fowlkes DL. Daclizumab induction/tacrolimus sparing: a randomized prospective trial in renal transplantation. Clin Transplant 2002; 16 [Suppl 7]: 30-33
11. Kuypers DRJ, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. Clin Transplant 2003; 17: 234-241
12. Vincenti F, Mendeze R, Rajagopalan PR et al. A phase I/II trial of anti-CD11a monoclonal antibody in renal transplantation. Am J Transplant 2001; 1 [Suppl]: 276 (Abstract)
13. Xu H, Tadaki DK, Elster EA et al. Humanized anti-CD154 antibody therapy for the treatment of allograft rejection in nonhuman primates. Transplantation 2002; 74: 940-943
14. Friend PJ, Hale G, Waldman H et al. Campath-1M - prophylactic use after kidney transplantation. Transplantation 1989; 48: 248-253
15. Calne R, Moffatt SD, Friend PJ et al. Campath 1H allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999; 68: 1613-1616
16. Knechtle SJ, Pirsch JD, Fechner JH et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003; 3: 722-730
17. Kirk AD, Hale DA, Mannon RB et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody Alemtuzumab (Campath-1H). Transplantation 2003; 76: 120-129
18. McGeown MG, Douglas JF, Donaldson RA et al. Ten-year results of renal transplantation with azathioprine and prednisolone as only immunosuppression. Lancet 1988; 1: 983-985
19. Vanrenterghem Y, Waer M, Ang K et al. Renal cadaveric transplantation after total lymphoid irradiation in patients with diabetes. Kidney Int 1983; 23 [Suppl 14]: S69-S73
20. Boots JM, Christiaans MH, Van Duijnhoven et al. Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. Transplantation 2002; 74: 1703-1709
21. Starlz TE, Murase N, Abu-Elmagd K et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003; 361: 1502-1510
22. Swanson SJ, Hale DA, Mannon RB et al. Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet 2002; 360: 1662-1664